The Experts below are selected from a list of 10062 Experts worldwide ranked by ideXlab platform
James J. Quattrochi - One of the best experts on this subject based on the ideXlab platform.
-
Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine
Neuropsychopharmacology, 1993Co-Authors: James J. Quattrochi, Adam N. Mamelak, Devin Binder, Julie Williams, J. Allan HobsonAbstract:Parenteral administration of the Serotonin-1 Agonist eltoprazine (0.0625 to 4.0 mg/kg [0.0002 to 0.016 mmol/kg]) in freely moving cats produced significant supression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mg/kg) and PGO wave activity (2 to 4 mg/kg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
-
Dynamic suppression of REM sleep by parenteral administration of the Serotonin-1 Agonist eltoprazine.
Sleep, 1992Co-Authors: James J. Quattrochi, Adam N. Mamelak, Julie A. Williams, Rittenhouse CAbstract:The purpose of this study was to determine the effects of the Serotonin-1 Agonist eltoprazine on the control of rapid eye movement (REM) sleep. Continuous polygraph recordings were performed for 15-17 days in four adult male cats. During the first 5 control days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received eltoprazine i.p. (1-2 mg/kg, b.i.d.). For the final 5 recovery days cats received saline alone. During the saline control period, the mean REM sleep percent was 13.8 +/- 0.91%. When eltoprazine was administered for the subsequent 5-7 days, the mean REM percent was reduced to 1.5 +/- 0.59%. During the 5-day recovery period, REM percent increased significantly (p less than 0.0001) above both control and drug injection values to a mean of 24.5 +/- 1.3% with a maximum on recovery day 1 of 28.4 +/- 2.6% (n = 4). In addition to REM suppression, eltoprazine produced other electroencephalographic changes: an increase in slow-wave sleep (S) percent without any change in overall wake (W) percent; an increase in electromyogram (EMG) amplitude; and a decrease in ponto-geniculo-occipital (PGO) wave activity. PGO wave frequency and REM% increased significantly during the recovery period. Thus our findings demonstrate REM and PGO suppression by eltoprazine and document dramatic rebound effects following its withdrawal.
Adam N. Mamelak - One of the best experts on this subject based on the ideXlab platform.
-
Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine
Neuropsychopharmacology, 1993Co-Authors: James J. Quattrochi, Adam N. Mamelak, Devin Binder, Julie Williams, J. Allan HobsonAbstract:Parenteral administration of the Serotonin-1 Agonist eltoprazine (0.0625 to 4.0 mg/kg [0.0002 to 0.016 mmol/kg]) in freely moving cats produced significant supression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mg/kg) and PGO wave activity (2 to 4 mg/kg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
-
Dynamic suppression of REM sleep by parenteral administration of the Serotonin-1 Agonist eltoprazine.
Sleep, 1992Co-Authors: James J. Quattrochi, Adam N. Mamelak, Julie A. Williams, Rittenhouse CAbstract:The purpose of this study was to determine the effects of the Serotonin-1 Agonist eltoprazine on the control of rapid eye movement (REM) sleep. Continuous polygraph recordings were performed for 15-17 days in four adult male cats. During the first 5 control days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received eltoprazine i.p. (1-2 mg/kg, b.i.d.). For the final 5 recovery days cats received saline alone. During the saline control period, the mean REM sleep percent was 13.8 +/- 0.91%. When eltoprazine was administered for the subsequent 5-7 days, the mean REM percent was reduced to 1.5 +/- 0.59%. During the 5-day recovery period, REM percent increased significantly (p less than 0.0001) above both control and drug injection values to a mean of 24.5 +/- 1.3% with a maximum on recovery day 1 of 28.4 +/- 2.6% (n = 4). In addition to REM suppression, eltoprazine produced other electroencephalographic changes: an increase in slow-wave sleep (S) percent without any change in overall wake (W) percent; an increase in electromyogram (EMG) amplitude; and a decrease in ponto-geniculo-occipital (PGO) wave activity. PGO wave frequency and REM% increased significantly during the recovery period. Thus our findings demonstrate REM and PGO suppression by eltoprazine and document dramatic rebound effects following its withdrawal.
J. Allan Hobson - One of the best experts on this subject based on the ideXlab platform.
-
Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine
Neuropsychopharmacology, 1993Co-Authors: James J. Quattrochi, Adam N. Mamelak, Devin Binder, Julie Williams, J. Allan HobsonAbstract:Parenteral administration of the Serotonin-1 Agonist eltoprazine (0.0625 to 4.0 mg/kg [0.0002 to 0.016 mmol/kg]) in freely moving cats produced significant supression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mg/kg) and PGO wave activity (2 to 4 mg/kg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
Rittenhouse C - One of the best experts on this subject based on the ideXlab platform.
-
Dynamic suppression of REM sleep by parenteral administration of the Serotonin-1 Agonist eltoprazine.
Sleep, 1992Co-Authors: James J. Quattrochi, Adam N. Mamelak, Julie A. Williams, Rittenhouse CAbstract:The purpose of this study was to determine the effects of the Serotonin-1 Agonist eltoprazine on the control of rapid eye movement (REM) sleep. Continuous polygraph recordings were performed for 15-17 days in four adult male cats. During the first 5 control days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received injections of 0.9% saline intraperitoneally (i.p.) twice per day (b.i.d.). Over the next 5-7 days cats received eltoprazine i.p. (1-2 mg/kg, b.i.d.). For the final 5 recovery days cats received saline alone. During the saline control period, the mean REM sleep percent was 13.8 +/- 0.91%. When eltoprazine was administered for the subsequent 5-7 days, the mean REM percent was reduced to 1.5 +/- 0.59%. During the 5-day recovery period, REM percent increased significantly (p less than 0.0001) above both control and drug injection values to a mean of 24.5 +/- 1.3% with a maximum on recovery day 1 of 28.4 +/- 2.6% (n = 4). In addition to REM suppression, eltoprazine produced other electroencephalographic changes: an increase in slow-wave sleep (S) percent without any change in overall wake (W) percent; an increase in electromyogram (EMG) amplitude; and a decrease in ponto-geniculo-occipital (PGO) wave activity. PGO wave frequency and REM% increased significantly during the recovery period. Thus our findings demonstrate REM and PGO suppression by eltoprazine and document dramatic rebound effects following its withdrawal.
Devin Binder - One of the best experts on this subject based on the ideXlab platform.
-
Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine
Neuropsychopharmacology, 1993Co-Authors: James J. Quattrochi, Adam N. Mamelak, Devin Binder, Julie Williams, J. Allan HobsonAbstract:Parenteral administration of the Serotonin-1 Agonist eltoprazine (0.0625 to 4.0 mg/kg [0.0002 to 0.016 mmol/kg]) in freely moving cats produced significant supression of electrophysiologic rapid eye movement (REM) sleep signs, ponto-geniculo-occipital (PGG) activity, and REM sleep behavior. The virtual total suppression of REM sleep (0.4%, 4.0 mg/kg) and PGO wave activity (2 to 4 mg/kg) in exchange for increasing amounts of non-REM (NREM) slow-wave sleep was a dose-dependent function of the amount of eltoprazine administered. Wakefulness was unaffected by eltoprazine regardless of dose. Concurrent with this dose-dependent suppression of REM was a dose-dependent increase in electroencephalographic synchrony and mean electromyographic amplitude. Since eltoprazine was found to shift the balance between REM and NREM sleep but did not change the balance between sleep and waking, it is a potentially useful tool for the investigation of serotonergic-cholinergic interaction.
